$ONCO
Onconetix, Inc. Stock $onco

$onco Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023039141 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$79.00K	$1.766M	$1.616M
YoY Change	-97.37%	9.31%
% of Gross Profit
Research & Development	$846.9K	$1.082M	$455.1K
YoY Change	-34.53%	137.81%
% of Gross Profit
Depreciation & Amortization	$0.00	$1.698K	$1.300K
YoY Change	-100.0%	30.62%
% of Gross Profit
Operating Expenses	$6.650M	$2.848M	$2.071M
YoY Change	54.83%	37.55%
Operating Profit	-$6.650M	-$2.848M	-$2.071M
YoY Change	54.83%	37.55%
Interest Expense	$214.0K	$1.620K
YoY Change	606.26%
% of Operating Profit
Other Income/Expense, Net	-$215.7K	$1.615K
YoY Change	-103.13%
Pretax Income	-$6.870M	-$2.847M	-$2.071M
YoY Change	61.09%	37.48%
Income Tax
% Of Pretax Income
Net Earnings	-$6.865M	-$2.847M	-$2.071M
YoY Change	60.98%	37.48%	535.6%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.43	-$0.18	-$0.34
Diluted Earnings Per Share	-$0.21	-$0.18	-$326.6K
COMMON SHARES
Basic Shares Outstanding	15.91M shares	15.91M shares	6.339M shares
Diluted Shares Outstanding	15.91M shares	15.91M shares	6.339M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.220M	$20.26M	$18.61M
YoY Change	-58.55%	8.85%
Cash & Equivalents	$9.223M	$21.26M	$18.61M
Short-Term Investments
Other Short-Term Assets	$690.0K	$2.146M	$328.8K
YoY Change	-44.88%	552.74%
Inventory	$1.172M
Prepaid Expenses	$685.4K	$780.2K
Receivables
Other Receivables
Total Short-Term Assets	$11.41M	$22.47M	$19.10M
YoY Change	-51.5%	17.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.12K	$14.21K	$15.40K
YoY Change	-20.58%	-7.73%
Goodwill
YoY Change
Intangibles	$17.91M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$420.0K	$15.50K	$217.1K
YoY Change	313.55%	-92.86%
Total Long-Term Assets	$18.34M	$29.71K	$232.5K
YoY Change	15269.7%	-87.22%
TOTAL ASSETS
Total Short-Term Assets	$11.41M	$22.47M	$19.10M
Total Long-Term Assets	$18.34M	$29.71K	$232.5K
Total Assets	$29.75M	$22.50M	$19.34M
YoY Change	25.87%	16.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.077M	$1.503M	$907.5K
YoY Change	113.44%	65.64%
Accrued Expenses	$1.420M	$1.293M	$1.893M
YoY Change	-31.75%	-31.71%
Deferred Revenue
YoY Change
Short-Term Debt	$8.620M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.13M	$2.809M	$2.801M
YoY Change	296.7%	0.27%
LONG-TERM LIABILITIES
Long-Term Debt	$4.540M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$4.540M	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.13M	$2.809M	$2.801M
Total Long-Term Liabilities	$4.540M	$0.00	$0.00
Total Liabilities	$16.67M	$2.809M	$2.801M
YoY Change	445.05%	0.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.09M	-$22.22M
YoY Change	136.65%
Common Stock	$169.00	$164.00
YoY Change	38.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$625.8K	$600.3K
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.08M	$19.69M	$16.53M
YoY Change
Total Liabilities & Shareholders Equity	$29.75M	$22.50M	$19.34M
YoY Change	25.87%	16.38%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$6.865M	-$2.847M	-$2.071M
YoY Change	60.98%	37.48%	535.6%
Depreciation, Depletion And Amortization	$0.00	$1.698K	$1.300K
YoY Change	-100.0%	30.62%
Cash From Operating Activities	-$1.780M	-$4.446M	-$886.1K
YoY Change	-44.07%	401.76%
INVESTING ACTIVITIES
Capital Expenditures	$6.080M	$1.819K	-$5.200K
YoY Change	-146959.9%	-134.98%
Acquisitions
YoY Change
Other Investing Activities	-$3.950M
YoY Change
Cash From Investing Activities	-$10.04M	-$1.819K	-$5.200K
YoY Change	242412.08%	-65.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-210.0K	-$48.95K	17.57M
YoY Change	-103.08%	-100.28%
NET CHANGE
Cash From Operating Activities	-1.780M	-$4.446M	-886.1K
Cash From Investing Activities	-10.04M	-$1.819K	-5.200K
Cash From Financing Activities	-210.0K	-$48.95K	17.57M
Net Change In Cash	-12.03M	-$4.497M	16.68M
YoY Change	-431.14%	-126.96%
FREE CASH FLOW
Cash From Operating Activities	-$1.780M	-$4.446M	-$886.1K
Capital Expenditures	$6.080M	$1.819K	-$5.200K
Free Cash Flow	-$7.860M	-$4.448M	-$880.9K
YoY Change	147.3%	404.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41294
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Blue Water Biotech, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-2262816
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 E. Fifth Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1900
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cincinnati
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	OH
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	45202
CY2023Q1	dei	City Area Code CityAreaCode	(513)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	620-4101
CY2023Q1	dei	Security12b Title Security12bTitle	Common stock, $0.00001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	BWV
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15905732	shares
CY2023Q1	us-gaap	Cash Cash	20255803	usd
CY2022Q4	us-gaap	Cash Cash	25752659	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	1000000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	780173	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	469232	usd
CY2023Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	366113	usd
CY2023Q1	bwv	Receivable From Related Parties ReceivableFromRelatedParties	70302	usd
CY2022Q4	bwv	Receivable From Related Parties ReceivableFromRelatedParties	35850	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	22472391	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	26257741	usd
CY2023Q1	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	15500	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	38617	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14210	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14089	usd
CY2023Q1	us-gaap	Assets Assets	22502101	usd
CY2022Q4	us-gaap	Assets Assets	26310447	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1503262	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1499296	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1292951	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2409128	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	12406	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	14021	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2808619	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3922445	usd
CY2023Q1	us-gaap	Liabilities Liabilities	2808619	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3922445	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16371597	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15724957	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15879230	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15265228	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	164	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	157	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42516726	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42331155	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	492367	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	459729	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	600264	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	566810	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22223144	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19376500	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	19693482	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22388002	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22502101	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26310447	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1766022	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1615569	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1082237	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	455092	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2848259	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	2070661	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2848259	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2070661	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1615	usd
CY2023Q1	us-gaap	Other Operating Income OtherOperatingIncome	1615	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2846644	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	15500	usd
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	5000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2070661	usd
CY2022Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	96359	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2846644	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2167020	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15910415	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6339435	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22388002	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	185578	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	33454	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2846644	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	19693482	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1446577	usd
CY2022Q1	bwv	Issuance Of Common Stock In Initial Public Offering Net IssuanceOfCommonStockInInitialPublicOfferingNet	2900000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	17138840	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	19322	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2070661	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	16534088	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2846644	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2070661	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	185578	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	19332	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1698	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1300	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-1615	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	321961	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-144546	usd
CY2023Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	34452	usd
CY2022Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	11991	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-23117	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	129454	usd
CY2022Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	87638	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1237493	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	896659	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-214311	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	351816	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4446083	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-886091	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1819	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5197	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1819	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5197	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	33454	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	18400000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	-822937	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-48954	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17572063	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4496856	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	16680775	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25752659	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1928474	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21255803	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18609249	usd
CY2023Q1	bwv	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	339593	usd
CY2022Q1	bwv	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	233804	usd
CY2023Q1	bwv	Deferred Offering Costs Previously Prepaid DeferredOfferingCostsPreviouslyPrepaid	-11020	usd
CY2023Q1	bwv	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	7	usd
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	45	usd
CY2022Q1	bwv	Initial Public Offering Costs Included In Accounts Payable InitialPublicOfferingCostsIncludedInAccountsPayable	104035	usd
CY2022Q1	bwv	Initial Public Offering Shares InitialPublicOfferingShares	2222222	shares
CY2022Q1	bwv	Price Per Share PricePerShare	0.00001
CY2022Q1	bwv	Public Of Per Share PublicOfPerShare	9
CY2023Q1	bwv	Initial Public Offering InitialPublicOffering	Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9 million, were $17.1 million.
CY2023Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	5626365	shares
CY2023Q1	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	33100000	usd
CY2023Q1	us-gaap	Investments And Cash InvestmentsAndCash	20300000	usd
CY2023Q1	us-gaap	Other Additional Capital OtherAdditionalCapital	19700000	usd
CY2023Q1	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	22200000	usd
CY2023Q2	bwv	Initial Consideration Amount InitialConsiderationAmount	20000000	usd
CY2023Q2	bwv	Amount Paid AmountPaid	6000000	usd
CY2023Q2	bwv	Due Amount DueAmount	9000000	usd
CY2024Q3	bwv	Due Amount DueAmount	5000000	usd
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.46875
CY2022Q2	bwv	Warrants Issuable Shares WarrantsIssuableShares	70849	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1180812	shares
CY2023Q1	us-gaap	Cash Cash	20255803	usd
CY2022Q4	us-gaap	Cash Cash	25752659	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	1000000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	21255803	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	25752659	usd
CY2023Q1	bwv	Prepaids Research And Development PrepaidsResearchAndDevelopment	208583	usd
CY2022Q4	bwv	Prepaids Research And Development PrepaidsResearchAndDevelopment	231981	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	484788	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	148789	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	86802	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	88462	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	780173	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	469232	usd
CY2022	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	15000	usd
CY2023Q1	bwv	Accrued Research And Development AccruedResearchAndDevelopment	549762	usd
CY2022	bwv	Accrued Research And Development AccruedResearchAndDevelopment	847747	usd
CY2023Q1	bwv	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	246316	usd
CY2022Q4	bwv	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	125000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	324051	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	1132859	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	26200	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	177600	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	109375	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	38750	usd
CY2023Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	37247	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	72172	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1292951	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2409128	usd
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16371597	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15724957	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15879230	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15265228	shares
CY2022Q1	bwv	Aggregate Purchase Shares AggregatePurchaseShares	2222222	shares
CY2022Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	9
CY2022Q1	us-gaap	Underwriting Expense Ratio UnderwritingExpenseRatio	0.08	pure
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	17100000	usd
CY2022Q4	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	5000000	shares
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	1
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	2
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	32638	shares
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.03
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	33500	usd
CY2023Q1	bwv	Remaining Shares RemainingShares	4500000	shares
CY2022Q2	us-gaap	Other Expenses OtherExpenses	6900000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2022Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	6.65
CY2023Q1	bwv	Percentage Of Purchase Warrants PercentageOfPurchaseWarrants	0.06	pure
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2.546
CY2023Q1	bwv	Agent Fee Percentage AgentFeePercentage	0.075	pure
CY2023Q1	bwv	Management Fee Percentage ManagementFeePercentage	0.01	pure
CY2023Q1	bwv	Out Of Pocket Expenses OutOfPocketExpenses	85000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	220997	shares
CY2023Q1	bwv	Percentage Of Common Stock Shares PercentageOfCommonStockShares	0.06	pure
CY2023Q1	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	298346	shares
CY2023Q1	bwv	Warrants Issuable Shares WarrantsIssuableShares	70849	shares
CY2023Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	70849	shares
CY2023Q1	bwv	Contigent Warrant Liability Description ContigentWarrantLiabilityDescription	The remaining 227,497 August Contingent Warrants were measured as a liability upon the close of the August Private Placement.
CY2023Q1	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	3900000	shares
CY2023Q1	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.03	pure
CY2023Q1	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	12000	usd
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	14000	usd
CY2022Q1	us-gaap	Shares Issued SharesIssued	1600000	shares
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2600000	shares
CY2023Q1	bwv	Issuance Options IssuanceOptions	965446	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.05
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.131	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.035	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.08
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	272000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	659000	usd
CY2023Q1	us-gaap	Insured Financial Obligations With Credit Deterioration Remaining Weighted Average Contract Period InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod	P1Y10M24D
CY2022Q2	us-gaap	Short Term Lease Payments ShortTermLeasePayments	14000	usd
CY2023Q1	us-gaap	Loss Contingency Date Of Dismissal LossContingencyDateOfDismissal	2023-04-30
CY2023Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	48000	usd
CY2023Q1	bwv	Lease Expense leaseExpense	4000	usd
CY2023Q1	bwv	Percentage Of Subscription PercentageOfSubscription	0.02	pure
CY2023Q1	bwv	Aggregate Amount AggregateAmount	115100000	usd
CY2023Q1	us-gaap	Payments For Fees PaymentsForFees	63000	usd
CY2023Q1	us-gaap	Grants Receivable GrantsReceivable	70000	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	36000	usd
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	1469102	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	780640	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	5264274	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	111111	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	6733376	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	891751	shares
CY2023Q1	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Consideration Transferred BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred	20000000	usd
CY2023Q1	us-gaap	Sale Leaseback Transaction Description Of Asset S SaleLeasebackTransactionDescriptionOfAssetS	the Company to pay the Seller up to an additional $80.0 million based on the Company’s net sales of ENTADFI® after closing (the "Milestone Payments"). The Milestone Payments are payable as follows: (i) $10.0 million is payable upon the first time the Company achieves net sales from ENTADFI® of $100.0 million during a calendar year, (ii) $20.0 million is payable upon the first time the Company achieves net sales from ENTADFI® of $200.0 million during a calendar year, and (3) $50.0 million is payable upon the first time the Company achieves net sales from ENTADFI® of $500.0 million during a calendar year. No more than one Milestone Payment shall be made for the achievement of each net sales milestone
CY2023Q1	bwv	Royalty Rate Percentage RoyaltyRatePercentage	0.06	pure
CY2023Q1	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	22500000	usd
CY2023Q1	bwv	Agreement Term AgreementTerm	P5Y
CY2023Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	487500	shares
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q1	us-gaap	Other Operating Income OtherOperatingIncome		usd
CY2023Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15910415	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6339435	shares
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2023Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022Q1	bwv	Deferred Offering Costs Previously Prepaid DeferredOfferingCostsPreviouslyPrepaid		usd
CY2022Q1	bwv	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants		usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2023Q1	bwv	Initial Public Offering Costs Included In Accounts Payable InitialPublicOfferingCostsIncludedInAccountsPayable		usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash		usd
CY2023Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001782107

Files In Submission

Name	View Source	Status
bwv-20230331_cal.xml	Edgar Link	unprocessable
bwv-20230331_pre.xml	Edgar Link	unprocessable
0001213900-23-039141-index-headers.html	Edgar Link	pending
0001213900-23-039141-index.html	Edgar Link	pending
0001213900-23-039141.txt	Edgar Link	pending
0001213900-23-039141-xbrl.zip	Edgar Link	pending
bwv-20230331.xsd	Edgar Link	pending
f10q0323ex10-1_bluewater.htm	Edgar Link	pending
f10q0323ex10-2_bluewater.htm	Edgar Link	pending
f10q0323ex31-1_bluewater.htm	Edgar Link	pending
f10q0323ex31-2_bluewater.htm	Edgar Link	pending
f10q0323ex32-1_bluewater.htm	Edgar Link	pending
f10q0323ex32-2_bluewater.htm	Edgar Link	pending
f10q0323_bluewater.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
bwv-20230331_lab.xml	Edgar Link	unprocessable
bwv-20230331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0323_bluewater_htm.xml	Edgar Link	completed
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONCO
Onconetix, Inc. Stock $onco

2023 Q2 Form 10-Q Financial Statement

#000121390023039141 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONCO Onconetix, Inc. Stock $onco

2023 Q2 Form 10-Q Financial Statement

#000121390023039141 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONCO
Onconetix, Inc. Stock $onco